Earnings call transcript: Chromadex’s Q4 2024 earnings beat forecasts, stock rises
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with record revenues, significant net income growth, and improved margins. The e-commerce channel and NIAGEN ingredient sales have also seen substantial increases. While there are uncertainties in R&D outcomes, the overall financial health and strategic product launches suggest a positive outlook. The Q&A section did not reveal major concerns that would offset these positives. Despite the lack of a share repurchase program, the company's cash flow and debt-free status support a positive sentiment.
Key Financial Performance
Total Net Sales (Q4 2024) $29,100,000, a 37% increase year over year.
Net Income (Q4 2024) $7,200,000, a substantial increase from $100,000 in Q4 2023.
Total Net Sales (Full Year 2024) $99,600,000, a 19% growth year over year.
Net Income (Full Year 2024) $8,600,000, a turnaround from a net loss of $4,900,000 in FY 2023.
Cash Flow from Operations (Full Year 2024) $12,100,000, up from $7,100,000 in the prior year.
Gross Margin (Q4 2024) 62.5%, improved by 150 basis points from 61% in Q4 2023.
Selling and Marketing Expenses (Q4 2024) 29.9% of net sales, improved by 90 basis points from 30.8% in Q4 2023.
General and Administrative Expenses (Full Year 2024) Decreased by $6,600,000 year over year.
Research and Development Expenses (Full Year 2024) Increased by $1,100,000 year over year.
Operating Income (Q4 2024) $7,100,000, compared to a $200,000 operating loss in Q4 2023.
Cash Balance (End of 2024) $44,700,000 with no debt.
Total NIAGEN Ingredient Sales (Q4 2024) Increased by 96% year over year.
E-commerce Channel Sales (Q4 2024) $17,300,000, a 30% increase year over year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NIAGEN Plus Product Line Launch: Launched NIAGEN IV and injections at clinics through a compound pharmacy network, with strong initial sales but faced supply chain delays.
Stick Packs: Introduced 300 mg stick packs with inulin, targeting younger consumers and workout cohorts, expecting to initiate a marketing campaign in 2025.
New Formulations: Plans to introduce new formulations of supplements complementary to TRU NIAGEN and reformulate existing products.
Market Expansion: Expanded NIAGEN IV availability to about 500 clinics nationwide, with expectations to double that by year-end.
E-commerce Growth: E-commerce channel saw a 30% increase in net sales, driven by improved performance on platforms like Amazon and Shopify.
Food Grade Ingredient Business: Food grade NIAGEN ingredient sales increased by 96%, with expectations for continued growth in 2025.
Operational Efficiency: Achieved gross margins of 61.8% for the full year, reflecting improved operational efficiencies and cost management.
Cash Flow: Generated $12.1 million in positive cash flow from operations in 2024.
Debt-Free Status: Ended the year with $44.7 million in cash and no debt.
Company Name Change: Announced plans to change the company name to better align with its strategic direction.
FDA Communication: Initiated communication with the FDA for an investigational new drug application for NR in treating ataxia telangiectasia.
Focus on Consumer Safety: Plans to leverage industry leadership to drive awareness of consumer safety and product excellence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: ChromaDex faces increasing competition from companies entering the NAD market, some of which engage in misleading practices, patent infringements, and false claims. This competitive landscape poses a risk to ChromaDex's market position and consumer trust.
Regulatory Issues: The company is advocating for more stringent actions from the FDA and FTC to prevent deceptive practices in the supplement industry, which could impact their operations and market integrity.
Supply Chain Challenges: ChromaDex experienced delays in the availability of pharmaceutical-grade NIAGEN due to supply chain issues, which have since been resolved. However, the potential for future supply chain disruptions remains a concern.
Economic Factors: Global market conditions and economic factors could affect ChromaDex's business operations and financial performance, as indicated in their forward-looking statements.
Tariff Impacts: Potential tariffs could have a minor impact on ChromaDex's international business, particularly in relation to their Watsons partnership, but the overall effect is expected to be minimal.
Research and Development Risks: The outcomes of ongoing clinical trials, such as the Parkinson's disease study, are uncertain and could significantly affect future business prospects and product development.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: ChromaDex reported record revenues of $29.1 million for Q4 2024, a 37% increase year over year, and total net revenues of $99.6 million for the full year, reflecting a 19% growth.
Product Launches: The company launched the NIAGEN plus product line and introduced NIAGEN IV and injections at clinics, which are on pace for significant growth.
FDA Communication: ChromaDex initiated communication with the FDA regarding an investigational new drug application for NR in treating ataxia telangiectasia.
Strategic Partnerships: The company continues to expand its partnerships, including with Watson’s, to enhance distribution of NIAGEN products.
Name Change: ChromaDex plans to change its company name to better represent its strategic direction.
2025 Revenue Outlook: ChromaDex projects approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships.
Gross Margin Expectations: A modest improvement in gross margins is anticipated due to supply chain optimizations and cost-saving initiatives.
R&D Investment: R&D expenses are expected to increase year over year while remaining stable as a percentage of net sales at 6%.
G&A Expenses: General and administrative expenses are projected to increase by approximately $5 million to $6 million due to investments in business growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the STICK PACS a little bit as far as, give us a sense of pull through on Amazon or your website and a sense of what’s the milligram size and any comments as far as pricing?
A:It’s three hundred milligrams per stick pack. It also has inulin in it, so it actually has other fiber benefits. We haven’t really emphasized the stick pack. It’s interesting, it’s very rare that people ask us about stick packs, but sales of stick packs have over the last couple of quarters, begun to increase. So we expect in 2025 to initiate more of a campaign behind it.
Q:The 1.3 adjustment on the royalties for the fourth quarter, you expect you said the second and final in the first quarter, that will also be 1.3 as well?
A:So just to clarify, that’s not a royalty adjustment. That’s the Elysium settlement. The royalty adjustment relates to Dartmouth. We reversed $3,500,000 in Q4 with regards to Dartmouth. That’s not going to reoccur.
Q:On the no park study, we would should we expect a readout or some commentary from the company in the third quarter or the fourth quarter?
A:We really don’t know. It’s a double blinded study. We expect them to share it with us, but we don’t know for sure that they will once they have the data compiled.
Q:Could you talk about the Food Grade Nitrogen segment sticking out because it’s been extremely strong in the back half of 2024?
A:Yes, we expect it to continue to grow. We’ve added a couple of other partners. As you know, we’re extremely selective about to whom we supply NIAGEN as an ingredient.
Q:Could you just expand a little bit on the drivers of your strong e commerce performance in the fourth quarter?
A:Well, as you know, we’ve always done extremely well on Amazon, but we’ve also now seen a nice improvement in our Shopify performance.
Q:What have you learned with the just as from the clinics, the customers at the IV clinics and what if any learnings there?
A:Yes, it is an easy transfer from NAD IV consumers to NIAGEN. In fact, I can tell you with confidence that anybody who has experienced NAD IV that then tries NIAGEN IV is hooked.
Q:Any thoughts on how tariffs might potentially impact sourcing or even parts of your international business like the Watsons and Hong Kong?
A:It’s possible that tariffs will have a small impact on the Watson business and on the food grade the pharma grade nitrogen business.
Q:Any other innovations that you’re able to talk about planned for the year?
A:We do plan to either introduce one or two new formulations of supplements that are complementary to TRU NIAGEN or reformulate a couple of the formulations that we have.
Q:What is the potential market opportunity for the Parkinson’s disease study?
A:We won’t know the data for quite a while, but there are ten million people globally diagnosed with Parkinson’s disease.
Q:Can you comment on the frequency of people doing NIAGEN IV?
A:So we really can’t answer that question right now.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the timing of the readout from the no park study, stating they really don’t know and that it’s a double-blinded study. They also did not provide specific details on the frequency of people doing NIAGEN IV, indicating they couldn't answer that question due to supply issues.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Affairs ChromaDex
Dartmouth
Dr Senior
FDA
NAD IV
NAD level
NIAGEN IV
NIAGEN ingredient
NMN
Officer ChromaDex
Parkinson disease
Roth Capital
Senior Vice
TRU NIAGEN
area
awareness
cell
clinic
company NAD
drug
food grade
group
income
issue
label
material
molecule
order
people
pharma
problem
reason
reversal
royalty
spin
stick pack
supply chain
tariff
thing
CDXC Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript
Positive3-5
The company reported record revenue growth and strong e-commerce performance, which are positive indicators. Despite some supply chain issues, management remains optimistic about growth, especially with the Niagen IV expansion and potential partnerships. The Q&A revealed uncertainties in the NO PARK study and NAD+ testing, but these were not major concerns. Overall, the positive revenue outlook and strong product development outweigh the minor uncertainties, suggesting a positive stock price movement in the near term.
Earnings call transcript: Chromadex’s Q4 2024 earnings beat forecasts, stock rises
Positive3-4
The earnings call shows strong financial performance with record revenues, significant net income growth, and improved margins. The e-commerce channel and NIAGEN ingredient sales have also seen substantial increases. While there are uncertainties in R&D outcomes, the overall financial health and strategic product launches suggest a positive outlook. The Q&A section did not reveal major concerns that would offset these positives. Despite the lack of a share repurchase program, the company's cash flow and debt-free status support a positive sentiment.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Positive11-1
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
CDXC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
